Overview
OncoHost provides PROphet®, an AI-powered precision oncology platform that analyzes proteomic patterns from a single pre-treatment blood sample to predict clinical benefit, resistance mechanisms, and toxicities in cancer patients. The tool supports clinical decision-making for immunotherapy and combination therapies, particularly in NSCLC, by combining systems biology, bioinformatics, and machine learning. It enables personalized treatment plans to improve patient outcomes and reduce unnecessary therapies.
Frequently asked questions
- What is PROphet® and how does it work?
- PROphet® is OncoHost's proprietary plasma-based proteomic pattern recognition platform that analyzes ~7,000 proteins from one blood sample using AI, systems biology, and machine learning to generate a score predicting clinical benefit and guiding therapy selection.
- What cancers does OncoHost's technology target?
- The platform focuses on precision oncology, with validated applications for NSCLC immunotherapy decisions and broader use in predicting responses to cancer therapies.
- Where is OncoHost located and what are its regulatory achievements?
- Headquartered in Binyamina, Israel, and Cary, North Carolina, USA; PROphet® provides clinically validated scores, named Top Precision Oncology Solution for 2025 by Life Sciences Review.